Quinton BioTech Labs Grows 3.3% in 2024 and Exceeds €8.5M

Quinton BioTech Labs, a biotechnology company specialising in the manufacture of products based on cold microfiltered seawater, closes 2024 with a growth of 3.3% compared to the previous year (exceeding the 8.2 million euros of 2023), reaching a global turnover of 8.5 million euros. This new milestone reflects the consolidation of its international strategy and the exponential growth of some of its most innovative business lines.

Quinton’s growth in 2024 has been marked by its solid performance in key markets, consolidating its presence and strengthening its international business model. Spain, one of the fastest-growing markets, has registered a significant increase of 13%, driven by the growth of its Quinton Medical line, which already accounts for 26% of domestic sales, consolidating its position as a benchmark in the sector in the face of the growing demand for seawater-based solutions.

The Czech Republic has seen a 15% growth, confirming Quinton’s expansion in Central Europe and its ability to adapt to markets with high demands on quality and health regulations. In Romania, the 4% increase reflects the brand’s consolidation and its commitment to efficient distribution in this country.

In addition to geographic growth, Quinton’s strategic commitment to outsourcing production has yielded exceptional results. The production of private labels in sachets and sprays has seen a spectacular increase of 300%. This milestone demonstrates the confidence of other companies in Quinton’s quality and production capacity, as well as its key role in innovation within the sector.

Quinton Sport soars with 120% growth and its launch in the US

One of the major drivers of growth in 2024 has been Quinton Sport, the hydration and recovery line for athletes. The turnover of this division has increased from 203,000 euros in 2023 to 450,000 euros in 2024, representing a growth of 120%. This progress has been driven, to a large extent, by its launch in the United States, consolidating the brand’s presence in a strategic market for the sports and health sector.

For the laboratories, innovation and expansion will continue to be strategic pillars, aligning with market trends and the needs of its customers. The company continues to strengthen its presence in international markets and explore new expansion opportunities in key sectors.

Francisco Coll, CEO of Quinton, highlights: ” Our strategy is based on excellence, innovation and internationalization. In 2025, we will continue to strengthen our global presence, boosting R&D and exploring new growth opportunities. The evolution of the market motivates us to continue offering solutions of the highest quality and with the scientific support that characterizes us .”

With these results, Quinton continues to demonstrate its ability to diversify its business and expand into strategic markets, consolidating its leadership in the sector of products based on cold microfiltered seawater.

__

(Featured image by Enelia Sandoval via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in pmfarma. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us